NEWS & PRESS
Syndivia Unveils New GeminiMab Site-Specific Conjugation Technology at World ADC London 2024
STRASBOURG (France) – March 14, 2024 – Syndivia is pleased to officially unveil GeminiMab, our next-generation hinge site-specific conjugation platform, at World ADC London 2024.
This new technology enables the creation of DAR1 and other low-DAR ADCs with improved stability, enhanced tumor penetration, and high-dose clinical potential. GeminiMab represents a major step forward for scalable, native IgG conjugation and sets the stage for a new class of ADCs optimized for therapeutic index.
Visitors to the conference are invited to explore the details in our poster #45, where we present the first public data on the platform. And of course, feel free to stop by and discuss – our team is always happy to exchange ideas with fellow ADC enthusiasts.
Syndivia continues to push the boundaries of ADC innovation, and we look forward to sharing more as the GeminiMab pipeline advances.
Syndivia Unveils New Clinical Asset Featuring Proprietary ADC Linker Technology
STRASBOURG (France) – April 22, 2024 – Syndivia is proud to announce the unveiling of a clinical asset showcasing its proprietary high-stability ADC linker technology (APN).
Developed in collaboration with Inatherys, this candidate marks a significant milestone in the field of oncology therapeutics. The new clinical asset, INA03, represents a potent transferrin-competitive antibody-drug conjugate with improved stability in plasma designed to target CD71, with the aim of revolutionizing acute leukemia treatment. This innovative ADC has been years in the making, with Syndivia and Inatherys jointly overcoming numerous challenges to bring this promising candidate into the clinic (ClinicalTrials.gov identifier: NCT03957915).
Renowned Nobel Laureate Jean-Marie Lehn Appointed Chairman of Syndivia's Scientific Advisory Board
STRASBOURG (France) – November 16, 2023 – Syndivia, a leading biotechnology company at the forefront of innovative DAR1 ADCs (antibody-drug conjugates with a drug-to-antibody ratio of 1), is excited to announce the appointment of Nobel Prize-winning chemist, Professor Jean-Marie Lehn, as the Chairman of the company's Scientific Advisory Board (SAB).
Professor Lehn, who was awarded the Nobel Prize in Chemistry in 1987 for his groundbreaking work on supramolecular chemistry, brings a wealth of expertise and experience to Syndivia. His leadership as Chairman of the SAB will play a pivotal role in guiding and advancing Syndivia's cutting-edge research and development initiatives in the field of ADCs.
Syndivia's CEO, Sasha Koniev, expressed excitement about the appointment, stating, "We are honored to welcome Professor Jean-Marie Lehn to Syndivia. His outstanding contributions to the field of supramolecular chemistry, coupled with his visionary approach to scientific innovation, align seamlessly with our commitment to pushing the boundaries of ADCs. We are confident that Professor Lehn's guidance will be instrumental in shaping the future of Syndivia."
As Chairman of the SAB, Professor Lehn will work closely with Syndivia's research and development teams, providing strategic insights and fostering collaboration with other scientific leaders. His role will contribute to advancing Syndivia's mission of developing breakthrough therapies for unmet medical needs.
Professor Jean-Marie Lehn commented on his new role, saying, "I am thrilled to join Syndivia and contribute to their pioneering efforts in drug discovery. The intersection of chemistry and biotechnology holds great promise, and I look forward to working with the talented team at Syndivia to drive innovation and make a lasting impact on healthcare."
About Syndivia: Syndivia is a biotechnology company dedicated to revolutionizing the field of ADC therapeutics through cutting-edge research and development. The company focuses on harnessing the distinctive properties of its proprietary ADC platform, which provides improved efficacy.
The Press release is available on PRNewswire
Syndivia and TVM Capital Life Science Announce Creation of Auricula Biosciences to Develop Innovative Therapy for Patients with K-Ras mutant malignancies
LUXEMBOURG – January 13, 2022 – TVM Life Science Innovation II SCSp announced the Fund’s investment establishing Auricula Biosciences, Inc., a company based in Wilmington, Delaware, USA.
Auricula Biosciences plans to develop a first-in-class targeted therapeutic for a broad set of K-Ras mutant malignancies to clinical proof-of-concept. This conjugate targets macropinocytosis, a unique feature of cancer cells harboring K-Ras mutations.
Full press release is available at TVM Capital.
Syndivia Receives €2M Deeptech Financing From Bpifrance to Advance Its Lead Immunoconjugate for Solid Cancers
STRASBOURG (France) – March 10, 2020 – Syndivia announced today that it will benefit from €2M deep tech financing from Bpifrance. Proceeds will be used to further fund the advancement of one company's drug candidate towards the clinic.
The Deeptech plan was initiated by the French government and has been deployed by Bpifrance since 2019 to support deep tech startups resulting from research based on breakthrough innovations. The main objective is to allow these companies to grow, and to stimulate innovation by strengthening the links between academia and the entrepreneurial world.
Sasha Koniev, CEO of Syndivia, said, "We are very grateful to Bpifrance for this generous support. This financing will largely accelerate the development of our lead immunoconjugate for various cancer indications, which to date have a very limited number of effective treatment options."
Commenting on this news, Alban Stamm, in charge of innovation at Bpifrance, said, "Syndivia, which initially emerged from the research of academic laboratories supported by SATT Conectus and reinforced with iLab 2014 (emergence) and 2015 (development) grants, succeeded in bringing together all the ingredients to meet technological challenges. At Bpifrance, we appreciate Syndivia's progress to date and especially value the team: initially composed of young researchers with strong entrepreneurial capacity, it surrounded itself with an experienced board bringing together all the key success factors of a biotech startup."
About Bpifrance
Bpifrance is the French national investment bank. It finances businesses – at every stage of their development – through loans, guarantees, equity investments and export insurances. Bpifrance also provides extra financial services such as training and consultancy to help entrepreneurs meet their challenges.
About Syndivia
Syndivia is a biotechnology company that is developing a pipeline of targeted therapies for solid cancers by leveraging a specific targeting of the tumor microenvironment and anatomical hallmarks of solid tumors. Syndivia's mission is to develop new therapies for patients with the most difficult-to-treat cancer indications.
Media Contact
Syndivia
Sasha Koniev, CEO
Phone: 00 33 3 67 10 42 20
Email: enquiry@syndivia.com
https://www.prnewswire.com/news-releases/syndivia-receives-2m-deeptech-financing-from-bpifrance-to-advance-its-lead-immunoconjugate-for-solid-cancers-301020574.html